Boston Scientific
(NYSE: BSX)
announced today that it began a limited market release of its VersaVue single-use flexible cystoscope.
VersaVue expands the company’s product offerings intended to help clinicians diagnose and treat urinary tract conditions. The scope, which received FDA clearance in October, provides visualization of the lining of the bladder and urethra. It displays images to perform various diagnostic procedures.
The scope may help optimize schedule and workflow by eliminating time associated with reusable scope reprocessing, repair and maintenance. A sterile-as-packaged cystoscope for every patient can help to eliminate the risk of infection from cross-contamination. VersaVue may also help reduce patient wait times associated with the lack of available reusable scopes.
Boston Scientific says the lightweight, compact system eases transportation across a variety of clinical settings, including rural clinics. The portable 14-inch VersaVue tablet displays high-definition images and video as well. It does not require additional equipment to view the live image.
Medimaging Integrated Solution developed and manufactures the VersaVue single-use flexible cystoscope. Boston Scientific exclusively sells it through a distribution agreement. It currently only has commercial availability in the U.S.
“By utilizing a new cystoscope for every procedure, the VersaVue single-use flexible cystoscope can help reduce post-procedure infections like urinary tract infections (UTIs) that can be associated with improper reprocessing of reusable scopes,” said Dr. Ron Morton, chief medical officer, Urology, Boston Scientific. “The addition of the VersaVue Single-Use Flexible Cystoscope helps round out the comprehensive suite of urologic solutions we’re able to offer to our customers and their patients.”
